Conference abstractPublished 16 May 2016
Interference with glutamine metabolism: a novel approach for treatment of acute myeloid leukemia
University of Maryland School of Medicine, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In contrast to normal cells, rapidly dividing leukemia cells reprogram their nutritional requirements to match an increased metabolic demand. The two main nutrient sources for growth and survival of cancer cells are glucose and glutamine. Depletion of glutamine or interruption of its cellular processes can be detrimental to leukemia cells but not normal cells. Asparaginases deplete amino acids asparagine and glutamine and are FDA-approved drugs for the treatment of acute lymphoblastic leukemia (ALL). The anti-leukemia effect of asparaginases in acute myeloid leukemia (AML) is not established. Here we describe the preclinical effect of different asparaginase products on the survival of AML cells with or without isocitrate dehydrogenase (IDH) mutations, which culminates in glutamine depletion resulting in disruption of protein synthesis downstream of mammalian target of rapamycin (mTOR) causing strong apoptotic and autophagic responses. The clinical experience with asparaginase in AML patients will also be discussed. Moreover, the cytotoxic effect of pharmacologic inhition of glutaminase, the enzyme that converts glutamine to ammonia and glutamate, will be reported in AML cells with different mutational status.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectDiabetes & Endocrinology
- SubjectHaematology
- BylineArticles whose byline prints “Ashkan Emadi”